Cancer and Blood Diseases

Overview

The Monash Partners Comprehensive Cancer Consortium (MPCCC) is recognised as the Cancer and Blood Diseases Theme. MPCCC is a strategic alliance of health service and research organisations working in partnership to improve cancer outcomes through integrated, collaborative and innovative research, service improvement and clinical care programs.

MPCCC comprises a network of partner hospitals and associated health services that deliver care for people with all types of cancers, integrated with a research network of more than 500 academic, clinical and health services researchers. The MPCCC provides a single portal for improvement in the diagnosis and management of cancer and blood diseases for the people of South and East Victoria, treating over 19,000 patients each year with around 80,000 episodes of care.

Our goal is to improve patient experience and outcomes across the cancer care continuum, through world-class research and quality improvement.  

This ambition will be realised by linking our expertise across basic, translational, clinical, health service, population health and epidemiological research with the service delivery expertise of our clinical partners.

Our Priorities

The Cancer and Blood Diseases Theme aims to:

  • Design and deliver a holistic and equitable cancer research and improvement agenda that addresses the needs of people affected by cancer
  • Build capacity for world-class innovations in cancer treatment by linking discovery, pre-clinical and clinical research
  • Drive improvements in cancer care through innovative research and improvement
  • Use data wisely and strategically to inform priorities and measure outcomes
  • Establish and maintain strategic collaborations to align cancer research and improvement activities with cancer, health and research policy agendas, and link activities with available resources
  • Establish and maintain appropriate governance and processes to lead and promote a world-class cancer research and improvement agenda.

Cancer and Blood Diseases Theme Leaders

The Theme is led by Professor Gail Risbridger, Professor Eva Segelov and Professor John Zalcberg.

Professor Gail Risbridger is Research Director at the Monash Partners Comprehensive Cancer Consortium and played an integral role both in the establishment of the consortium and Monash Partners.

Read More

She is a National Health and Medical Research Council (NHMRC) research fellow and a career academic and researcher with more than 20 years’ experience in prostate cancer research and men’s health.

Professor Eva Segelov is Director of Oncology at Monash Health and Professor of Oncology in the Department of Medicine, Monash University, and has accepted the role of Acting Clinical Director of SMICs and MPCCC.

Read More

Previously, Eva worked as a clinical academic and senior staff specialist in medical oncology at the University of New South Wales. Her clinical focus has been in the management of patients with breast, upper and lower gastrointestinal cancer and neuroendocrine tumours, while Eva’s research interests are in clinical trials and associated translational research.

Professor John Zalcberg is Professor of Cancer Research in the School of Public Health and Preventive Medicine at Monash University.

Read More

Prior to this appointment he served as Director of the Division of Cancer Medicine at the Peter MacCallum Centre in Melbourne for 17 years.

 

Our Theme Executive

Supporting the Theme leaders is an internationally respected team of multi-disciplinary cancer and blood disease specialists who are committed to the Theme’s vision and dedicated to delivering its programs. Members of the MPCCC Cancer and Blood Diseases Theme Steering Committee include:

Professor Ian Davis
Associate Professor Jeremy Millar
Associate Professor Ron Firestein
Professor David Kissane
Professor Harshal Nandurkar
Associate Professor Paul McMurrick
Associate Professor Gary Richardson
Professor Mark Shackleton
Dr Zee Wan Wong


Governance Group

In addition to the Theme Executive and Steering Committee, a Governance Group has been appointed to provide financial authority and prioritisation, review deliverables and ensure policy alignment across the partnership.

MPCCC Research Programs

MPCCC’s activities will be delivered through three interconnected ‘Collaborative Platforms’ that reflect our commitment to patient-centred care and make optimal use of the world-class expertise in scientific and clinical research, cancer service delivery and cancer outcomes data within our partner organisations.    

Collaborative Platforms

Platform 1

USING DATA AS A FOUNDATION FOR HIGH-QUALITY CANCER CARE


Collection of clinical cancer data is accepted as critical for planning, evaluating and measuring quality of care and patient outcomes. Clinical Quality Registries are endorsed by the Australian Commission for Safety and Quality in Healthcare as a method of driving continuous improvement in clinical practice.

This Collaborative Platform aims to:

  1. Establish the MPCCC Centre for Cancer Outcomes Excellence
  2. Measure and report cancer outcome data to drive improvements in quality of care    
  3. Use data to inform Optimal Care Pathways and best practice care
  4. Real-time collection and clinical use of Patient-Reported Outcome Measures (PROMS) and Patient-Reported Experience Measures (PREMS)

Platform 2

IMPROVING CANCER OUTCOMES THROUGH INNOVATIVE RESEARCH


The initial focus of this collaborative platform will be to ensure our patients have equitable access to the latest molecular and immunome profiling technologies through a world class Precision Oncology Program.

MPCCC’s Precision Oncology Program aims to:

  1. Establish the MPCCC Precision Oncology Tumour Board to inform the selection and sequencing of therapies in patients whose cancer is resistant to standard treatments
  2. Foster clinical trials to provide our patients with access to the latest precision oncology therapies
  3. Establish a Clinical Fellowship program to develop future skill sets and career pathways for Precision Oncology.

Platform 3

INCREASING SERVICE CAPACITY TO ADDRESS PATIENT NEEDS THROUGH INNOVATIVE SHARED CARE MODELS 


Traditional models of specialist-driven cancer care are focussed on care provided in hospital settings. This can present a significant challenge for patients, particularly those from non-metropolitan settings, who need to travel for treatment and follow-up appointments.

MPCCC’s Shared Care Platform aims to:

  1. Establish and test approaches for shared care across hospital, primary care and community care settings
  2. Build capacity within the MPCCC region for high-quality psycho-oncology and supportive care services.


You can find out more about Monash Partners cancer work here.